英文字典,中文字典,查询,解释,review.php


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       


安装中文字典英文字典辞典工具!

安装中文字典英文字典辞典工具!










  • FDA approves imetelstat for low- to intermediate-1 risk myelodysplasti
    The recommended imetelstat dosage is 7 1 mg kg administered as an intravenous infusion over 2 hours every 4 weeks This review used the Assessment Aid , a voluntary submission from the applicant
  • Updated NCCN Guidelines Recommend Imetelstat for Anemia in Lower-Risk MDS
    Among patients with ring sideroblast–positive disease and symptomatic anemia, imetelstat is recommended as a Category 1 second-line treatment following luspatercept in those with a maximum serum EPO of 500 mU mL Patients received a median of 8 treatment cycles for both imetelstat (IQR, 5-17) and placebo (IQR, 6-15) after a median follow
  • Updated NCCN Guidelines Recommend Imetelstat to Treat Anemia in Lower . . .
    Imetelstat is an liquidated oligonucleotide telomerase inhibitor approved for treating adult patients with low-to-intermediate-1 risk MDS with transfusion-dependent anemia 1 The first-in-class treatment inhibits telomerase enzymatic activity and is the first and only telomerase inhibitor approved by the FDA
  • Imetelstat for anemia in lower-risk myelodysplastic syndromes: A . . .
    Imetelstat (Rytelo; Geron Corpo-ration) was approved by the FDA on June 6, 2024, as a treatment for transfusion-dependent anemia in patients with lower-risk MDS who have not responded to, lost response to, or are ineligible for ESAs 10 The Institute for Clinical and Economic Review (ICER) conducted a systematic literature review and cost-effectiveness analysis to evaluate the clinical and
  • NCCN Recommends Imetelstat for Symptomatic Anemia in Lower . . . - OncLive
    The guideline update follows the June 2024 FDA approval of imetelstat for the treatment of adult patients with low- to intermediate-1–risk MDS and transfusion-dependent anemia requiring at least
  • Institute for Clinical and Economic Review Publishes Evidence . . . - ICER
    “Imetelstat is a new treatment option for adults with low-to-intermediate MDS and transfusion-dependent anemia While available clinical evidence suggests that imetelstat may reduce or eliminate the need for transfusions, its impact on the severe fatigue that often accompanies MDS anemia is less clear
  • Imetelstat (Rytelo): a promising treatment for adults with lower-risk . . .
    These molecular discoveries underscore Imetelstat’s capacity to impact the course of MDS, setting it apart from other treatments that chiefly target anemia-related symptoms When compared to a placebo, Imetelstat was linked in clinical trials to a noticeably greater number of red blood cell transfusion independence (RBC-TI)
  • INDICATIONS AND USAGE DOSAGE AND ADMINISTRATION ADVERSE . . . - Geron
    RYTELO (imetelstat) for injection, for intravenous use Initial U S Approval: 2024 INDICATIONS AND USAGE RYTELO is an oligonucleotide telomerase inhibitor indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more


















中文字典-英文字典  2005-2009